[Mycetoma and their treatment].
Mycetoma are chronic subcutaneous infections, endemic in dry tropical regions. It can be caused either by actinomycetes or by fungi, presenting as filamentous grains in vivo. The foot is the most common localization. The main complication is osseous involvement. Patients are rural workers living in areas situated far from medical centers. Too often, they reach well-equipped hospitals with advanced mutilating lesions. Early case detection is the first condition for good therapeutic results. Clinical presentations of actinomycetoma and eumycetoma are similar, only biological diagnosis can distinguish the two etiological forms. This distinction is essential as medical therapy for each is radically different. Precise identification of the causal agent is required for targeted treatment but it can only be realized in rare specialized laboratories. For actinomycetoma, standard therapy is trimethoprim-sulphamethoxazole (STX). Duration of treatment period is one-year minimum. In case of poor response to STX or high risk of dissemination, a combination with amikacin gave high cure rate. Other options as amoxicillin-clavulanate are available. Medical cure of actinomycetoma is generally obtained with antibiotic treatments and surgical indications are exceptional. Disappointing results were observed using antifungal in the treatment of eumycetoma and medical therapy must be completed with surgical excision. Itraconazole is now the most used drug, new triazoles are on evaluation.
Service de parasitologie-mycologie, hôpital Saint-Antoine, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France. Electronic address: michel.develoux@sfr.fr.
M
M
Develoux
D039903:Actinobacteria / Q000187:drug effects / Q000472:pathogenicity; D000935:Antifungal Agents / Q000145:classification / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D008271:Mycetoma / Q000188:drug therapy* / Q000382:microbiology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000935:Antifungal Agents; D017964:Itraconazole; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
Actinomycetoma; Actinomycétomes; Eumycetoma; Eumycétomes; Itraconazole; Medical treatment; Traitement médical; Trimethoprim–sulfamethoxazole; Triméthoprime–sulfaméthoxazole